Skip to main content
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 2002 Sep;78(923):538–540. doi: 10.1136/pmj.78.923.538

Vaccination against hepatitis B infection in patients with end stage renal disease

K Bel'eed 1, M Wright 1, D Eadington 1, M Farr 1, L Sellars 1
PMCID: PMC1742496  PMID: 12357014

Abstract

Background: Experience of hepatitis B vaccination in a contemporary renal replacement programme is reported.

Methods: A total of 406 patients were involved: 214 on haemodialysis, 97 on continuous ambulatory peritoneal dialysis, 67 predialysis (serum creatinine >400 µmol/l), and 28 with a failing transplant. Primary vaccination comprised recombinant hepatitis B vaccine (Engerix B) 40 µg intramuscularly at 0, 1, 2, and 3 months. Booster doses were administered three monthly if anti-HBs titre was <100 IU/l.

Results: Uptake of vaccine was 61% (haemodialysis 70%, continuous ambulatory peritoneal dialysis 62%, predialysis 31%, transplant 61%, p<0.0001). Primary seroconversion occurred in 64% of vaccinated patients (anti-HBs; 10–100 U/l, 33%; >100 U/l, 31%). Booster doses led to further improvement in immunity in 66/115 (57%) patients after a first and 8/20 (40%) patients after a second booster dose, but uptake was again poor (first booster 74%, second 31%). Seroprotection declined unexpectedly rapidly; after a mean of 16 months 71/115 patients (62 %) had a significant fall in their anti-HBs titres; 30/115 (26%) lost detectable antibody.

Conclusions: Routine hepatitis B vaccination of patients with end stage renal failure is logistically difficult to administer on a large scale; primary seroconversion is relatively poor, but improves after repeated booster doses; protective anti-HBs titres decline rapidly, and yearly antibody checks with selective booster doses will be required to maintain seroprotection. The cost effectiveness of a vaccination programme will vary greatly depending on the prevalence of hepatitis B in the population at risk.

Full Text

The Full Text of this article is available as a PDF (89.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Buti M., Viladomiu L., Jardi R., Olmos A., Rodriguez J. A., Bartolome J., Esteban R., Guardia J. Long-term immunogenicity and efficacy of hepatitis B vaccine in hemodialysis patients. Am J Nephrol. 1992;12(3):144–147. doi: 10.1159/000168436. [DOI] [PubMed] [Google Scholar]
  2. Eddleston A. Modern vaccines. Hepatitis. Lancet. 1990 May 12;335(8698):1142–1145. doi: 10.1016/0140-6736(90)91138-z. [DOI] [PubMed] [Google Scholar]
  3. Geerlings W., Tufveson G., Brunner F. P., Ehrich J. H., Fassbinder W., Landais P., Mallick N., Margreiter R., Raine A. E., Rizzoni G. Combined report on regular dialysis and transplantation in Europe, XXI, 1990. Nephrol Dial Transplant. 1991;6 (Suppl 4):5–29. [PubMed] [Google Scholar]
  4. Hadler S. C., Francis D. P., Maynard J. E., Thompson S. E., Judson F. N., Echenberg D. F., Ostrow D. G., O'Malley P. M., Penley K. A., Altman N. L. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med. 1986 Jul 24;315(4):209–214. doi: 10.1056/NEJM198607243150401. [DOI] [PubMed] [Google Scholar]
  5. Jibani M. M., Heptonstall J., Walker A. M., Bloodworth L. O., Howard A. J. Hepatitis B immunization in UK renal units: failure to put policy into practice. Nephrol Dial Transplant. 1994;9(12):1765–1768. [PubMed] [Google Scholar]
  6. Navarro J. F., Teruel J. L., Mateos M. L., Marcen R., Ortuno J. Antibody level after hepatitis B vaccination in hemodialysis patients: influence of hepatitis C virus infection. Am J Nephrol. 1996;16(2):95–97. doi: 10.1159/000168977. [DOI] [PubMed] [Google Scholar]
  7. Peces R., de la Torre M., Alcázar R., Urra J. M. Prospective analysis of the factors influencing the antibody response to hepatitis B vaccine in hemodialysis patients. Am J Kidney Dis. 1997 Feb;29(2):239–245. doi: 10.1016/s0272-6386(97)90036-6. [DOI] [PubMed] [Google Scholar]
  8. Propst T., Propst A., Lhotta K., Vogel W., König P. Reinforced intradermal hepatitis B vaccination in hemodialysis patients is superior in antibody response to intramuscular or subcutaneous vaccination. Am J Kidney Dis. 1998 Dec;32(6):1041–1045. doi: 10.1016/s0272-6386(98)70081-2. [DOI] [PubMed] [Google Scholar]
  9. Shusterman N., Singer I. Infectious hepatitis in dialysis patients. Am J Kidney Dis. 1987 Jun;9(6):447–455. doi: 10.1016/s0272-6386(87)80070-7. [DOI] [PubMed] [Google Scholar]
  10. Szmuness W., Prince A. M., Grady G. F., Mann M. K., Levine R. W., Friedman E. A., Jacobs M. J., Josephson A., Ribot S., Shapiro F. L. Hepatitis B infection. A point-prevalence study in 15 US hemodialysis centers. JAMA. 1974 Feb 25;227(8):901–906. doi: 10.1001/jama.227.8.901. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES